Proprietary Blood Biomarker Testing Services (MSDA Assay)

The contract seeks to secure proprietary blood biomarker testing services for Veterans with multiple sclerosis using an 18-biomarker assay designed to measure disease activity. The scope includes the full lifecycle of specimen analysis, scoring, and generation of detailed reports to support clinical decision-making, with all work to be performed at a designated location in Detroit, Michigan. The testing service is intended to provide objective, data-driven insights into multiple sclerosis progression and treatment response, leveraging a proprietary technology to enhance patient care within the Veterans Health Administration. This subcontract, issued under NAICS code 541380, is managed by the Department of Veterans Affairs through the 250-NETWORK Contract Office 10 and carries a response deadline of May 6, 2026. All work must be completed in alignment with the VA’s standards for quality and timeliness, ensuring Veterans receive timely and accurate diagnostic information. The contract does not specify a set-aside category, and while no point of contact is listed, the performance location and agency oversight imply a focus on operational efficiency and integration with existing VA medical systems.